BOTHELL, Wash. (AP) — The FDA will conduct a faster review of Seattle Genetics Inc.’s cancer drug candidate SGN-35, the biotechnology company said Monday. Seattle Genetics said the FDA granted fast track status to SGN-35 as a treatment for Hodgkin’s disease, meaning it will conduct a six-month review of the drug instead of the usual 10 months. The company plans to ask for FDA approval of SGN-35 in 2011, and hopes to launch the drug the following year.
